Using exome or transcriptome data from more than 400 metastatic, castration-resistant prostate cancer cases, researchers identified survival-related alterations in the RB1 gene.
The test is designed to determine breast cancer risk by analyzing a number of factors including breast density, breast biopsy history, and a polygenic score.
Take2 was founded by Chinese University of Hong Kong researchers and will commercialize a cell-free DNA test for early cancer detection.
The next-generation sequencing assay is intended for use in identifying patients with ROS1, NTRK1-3, and ALK gene fusions in advanced solid tumors.
Last week, GenomeWeb's readers were most interested in concerns and controversies about genetic ancestry testing, particularly in minority communities.
The company recognized total first quarter revenues of $16.4 million and a net loss of $30.3 million.
An epigenome-wide association study of major psychosis uncovered hypomethylation at an enhancer that targets a gene involved in dopamine synthesis.
The company plans to offer 5.5 million shares of its common stock at $23.25 per share, raising around $127.9 million.
The company, which also trades on the Australian Securities Exchange, has 45 days to submit a plan to the Nasdaq as to regaining compliance.
The diagnostic will now be a contracted service with Anthem Blue Cross of California and 10 of its affiliated health plans.
The companies will develop analytics tools and leverage the Syapse Learning Health Network in an effort to shorten the time to market for new cancer therapies.
Genomic data for almost 300 ancient Eurasian horses points to lost equine lineages, horse relationships that reflect human interactions, and a recent loss in genetic diversity.
The FBI approved the MiSeq FGx Forensic Genomics System for use by forensic labs for generating DNA profiles for the National DNA Index System.
Year-over-year revenues increased on strong demand for the company's Helios and Hyperion imaging mass cytometry systems.
The firm said total revenues rose to $461.4 million from $431.7 million in the first quarter of 2018, beating analysts' consensus estimate of $450.1 million.
Researchers used the platform to identify small synthetic molecules that disrupt the editing activity of the SpCas9 nuclease.
The companies are using Strata's biomarker technology to identify genomic subpopulations of cancer patients who respond to Arcus' investigational immunotherapy drug.
A CTC and ctDNA analysis suggests that the number of alterations affecting the androgen receptor can offer survival insights for TP53 mutation-free advanced cancer cases.
Most head and neck cancer patients saw a decline in oral HPV DNA after treatment, but those who did not were more likely to experience disease recurrence.
Mismatch repair-deficient tumors with many insertion-deletion mutations and enhanced microsatellite instability responded better to anti-PD-1 immunotherapy.
Consumer genomics companies have endeavored to reach out to minority communities with sometimes contentious results.
The companies will commercialize Predigraft, a data analysis tool that provides early predictions of risk for allograft rejection and transplant loss.
University of Idaho researchers model the scientific discovery process to examine the link between reproducibility and scientific truth.
A bill passed by a US House of Representatives appropriations subcommittee would give scientific agencies including the National Science Foundation boosts in funding.
Relocating USDA agencies outside of Washington, DC, may make them less effective, critics of the move tell NPR.
In PLOS this week: genes that help Borrelia burgdorferi survive in ticks, CiliaCarta collection of about 1,000 suspected cilia genes, and more.